Brief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
18/05/2023 21:22
May 18 (Reuters) - Shin Nippon Biomedical Laboratories
Ltd 2395.T :
* SATSUMA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF
505(B)(2)
NDA FOR STS101, A NOVEL AND INVESTIGATIONAL DIHYDROERGOTAMINE
(DHE) NASAL POWDER PRODUCT FOR THE ACUTE TREATMENT OF MIGRAINE
* SATSUMA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF
505(B)(2)
NDA FOR STS101, A NOVEL AND INVESTIGATIONAL DIHYDROERGOTAMINE
(DHE) NASAL POWDER PRODUCT FOR ACUTE TREATMENT OF MIGRAINE
* SATSUMA PHARMACEUTICALS INC: JANUARY 2024 PDUFA DATE
EXPECTED
Source text for Eikon: ID:nGNX2bBgNS
Further company coverage: 2395.T
((Reutersbriefs@thomsonreuters.com;))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon